AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases.
It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications.
The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019.
Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Country | United States |
IPO Date | Sep 14, 2022 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 51 |
CEO | Natalie C. Holles |
Contact Details
Address: 300 Technology Square Cambridge, Massachusetts United States | |
Website | https://www.thirdharmonicbio.com |
Stock Details
Ticker Symbol | THRD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001923840 |
CUSIP Number | 88427A107 |
ISIN Number | US88427A1079 |
Employer ID | 83-4553503 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Natalie C. Holles | Chief Executive Officer & Director |
Jennifer Dittman | Chief Operating Officer |
Christopher Murphy | Chief Financial & Business Officer |
Dennis Dean Ph.D. | Chief Non-Clinical Development Officer |
Dr. Christopher J. Dinsmore Ph.D. | Chief Scientific Officer |
Dr. Edward R. Conner M.D. | Chief Medical Officer |
Julie Person | Chief Administrative Officer |
Ommer Chohan | Treasurer & Secretary |
Steven P. Sweeney | Senior Vice President of Development Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 12, 2024 | SC 13D/A | [Amend] Filing |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | 4 | Filing |
Nov 07, 2024 | 8-K | Current Report |
Nov 07, 2024 | 10-Q | Quarterly Report |
Nov 05, 2024 | SC 13D/A | [Amend] Filing |
Nov 05, 2024 | 4 | Filing |
Oct 31, 2024 | 4 | Filing |